Introduction
Hemoglobinopathies belong to distinctive classes of genetic disorders associated with the pathophysiology of the red blood cell, an oxygen carrier molecule. Sickle cell disease and thalassemia are among the most common hemoglobinopathies caused by mutations in genes for the globin chains of hemoglobin. Such conditions may lead to devastating complications such as anemia, pain crises, organ damage, and decreased life expectancy.
Standard therapies available for sickle cell anemia, like blood transfusion and iron chelation, have the principal disadvantage that they are merely palliative & are associated with their problems. Bone marrow transplant does seem to have curative potential but is hampered by limited donor availability and the risk of graft-versus-host disease. Hence, a need for gene therapy was developed for treatment. Gene therapy is the treatment that seeks to repair the genetic defect responsible for the disorder or to supply the cells with a normal gene of the defective gene to ensure the continuity of hemoglobin status.
Modified nucleases, the most popular of which is the CRISPR-Cas9 technology, have greatly enhanced gene therapy capabilities, allowing for the targeted incisions of specific genetic alteration. Currently, clinical trials are being conducted to assess the safety and effectiveness of these gene therapy techniques for hemoglobinopathies with encouraging results from early investigations.
What Are Hemoglobinopathies and How Do They Affect the Body?
Hemoglobinopathies are diverse hereditary blood disorders characterized by structural and functional abnormalities in hemoglobin molecules. These proteins in red blood cells transport oxygen from the lungs and carbon dioxide from the respiratory system to and from body tissues, respectively. Hemoglobin has two subunits, which are polypeptides called alpha-globin and beta-globin. These two polypeptide-chain-bearing genes can be altered by point mutations that lead to various types of hemoglobin abnormalities, with sickle cell disease and thalassemia being the most prevalent types.
-
Sickle Cell Disease: Sickle cell disease is a disorder that occurs due to a mutation in the HBB gene responsible for hemoglobin production, thus leading to another form of hemoglobin called hemoglobin S (HbS) rather than hemoglobin A (HbA). Since the HbS has a much lower solubility than the normal hemoglobin, the structure tends to polymerize under deoxygenated conditions, leading red blood cells to sickle. These abnormally shaped cells are often trapped in blood vessels, leading to blockage and pain characterized as vaso-occlusive crises. Compared to normal cells, sickle cells' rigid and malformed structure makes them more prone to rupture, leading to chronic hemolytic anemia. Being a relatively acute disease, sickle cell disease will also have debilitating effects, particularly over age, leading to stroke, acute chest syndrome, organ damage, and susceptibility to infections.
-
Thalassemia: Thalassemias are conditions that arise due to various mutations that impair the production of either the alpha or beta globin chains of blood hemoglobin. In beta-thalassemia, the HBB gene mutations cannot produce the beta-globin chains, increasing alpha chains and their complex formation. The young hemoglobin molecules produced in excess are unstable and precipitate in the red blood cells, leading to ineffective RBC production and causing anemia. In alpha-thalassemia, genetic events that involve the HBA1 and HBA2 genes result in diminishing or entirely halting the synthesis of alpha-globin chains. Generally, depending on the number of affected genes, alpha-thalassemia ranges from mild anemia deficiency to a lethal striking form, known as hydrops fetalis, chronic in pregnancy with inevitable demise before or soon after delivery. Like sickle cell disease, thalassemia creates serious complications within the individual's body owing to the heterogeneous complementation of the alphabet presented by hemoglobin. The resulting anemia often features symptoms of fatigue, weakness, and shortness of breath. In addition, chronic inadequate oxygen supply to tissues over time can lead to nutritional erosion of several body organs, including the heart, lungs, kidneys, and liver.
How Does Gene Therapy Work in Treating Hemoglobinopathies?
Gene therapy for hemoglobinopathies is the great hope for successful rehabilitation regimes of these genetic diseases by targeting the causal factor. These genes are responsible for producing abnormal hemoglobin. It involves either repairing the genetic defects that result in hemoglobinopathies or transfecting the patient’s hematopoietic stem cells (HSCs) with a normal type. HSCs are the immature cells found in bone marrow, which develop into various blood cells, including the red blood cells that carry the hemoglobin. Therefore, because these stem cells are self-renewal, gene therapy aims at ensuring an uninterrupted source of normal red blood cells synthesizing normal hemoglobin.
Gene therapy depends a lot on one of the techniques, which is viral vectors. Usually created from lentivirus or retrovirus, these vectors are modified to bring an appropriate gene into the patient’s HSCs. Once the vector brings the therapeutic gene inside the HSCs, these cells can be transplanted to the patient, from where they will be sent to the marrow cavity and begin producing erythrocytes containing normal hemoglobin. This method has helped to alleviate the need for total dependence on regular blood transfusions in hemoglobinopathies patients.
Another interesting strategy is based on gene editing technologies using CRISPR-Cas9 as the most popular tool. With the help of CRISPR-Cas9, specific mutations can be targeted to alter segments in the genome that are abnormal to the patient. In the case of hemoglobinopathies, CRISPR-Cas9 could be applied to either edit the mutation in the HSCs directly or to activate the expression of fetal hemoglobin, which is the normal form of hemoglobin that is lost during postnatal development but has been shown to overcome the defective adult forms in those disorders. By doing so to the HSCs, it is anticipated that CRISPR-Cas9 will be able to cure the disease permanently by the fact that no matter how many more cells of blood derived from these modified stem cells will be produced in the future, they will all be healthy, containing normal hemoglobin.
What Are the Challenges Associated With Gene Therapy for Hemoglobinopathies?
Although gene therapy for hemoglobinopathies holds promise, it also faces several issues that must be tackled to provide the required safety, effectiveness, and acceptance of the therapeutic procedure. One of the foremost challenges remains the safety and targeting of gene editing systems. Genes can be altered by technologies such as CRISPR-Cas9. However, precision can also produce unintended additional edits at unwanted DNA sites other than where it was intended. For example, product mutations may acquire undesired effects because they may induce diseases like cancer and other genetic anomalies that were not generally caused. So, further improving the specificity of such gene editing systems is important to reduce their negative effects and protect the well-being of the patients.
Another substantial challenge is ensuring that the expression of the therapeutic gene is long-lasting. In the case of gene therapy, the engrafted or repaired gene needs to be integrated into the patient's hematopoietic stem cells for the long term and perform its function for the rest of the patient‘s life. However, it may be challenging to maintain the activity of the therapeutic gene and the synthesis of normal hemoglobin in amounts necessary for the patient over time. Some issues include the loss of therapeutic gene activity due to the silencing of the exogenously incorporated gene and the attrition of the altered cells over time, which can affect the success of the treatment.
It is worth noting that the complexity of surgery related to the administration of gene therapy is also a significant obstacle. Infusion of genetically modified hematopoietic stem cells after they have been harvested from a patient, modified, and returned to the patient is not only a long but also a tortuous and labor-upholding process that requires concerted technology. Gene transfer is also important; therapeutic genes must be efficiently delivered into enough stem cells to produce the desired biological outcome. One more critical aspect that can affect the overall efficiency of the treatment is helping the modified stem cells to integrate into the bone marrow and start generating erythrocytes properly.
Moreover, the application of gene therapy for hemoglobinopathies has to consider the ethical challenges that may arise during the process. The intention to change someone’s genetic constitution or the entire population by allowing genes to be manipulated provides a rationale for ethical speculators. There is also the matter of access and fairness since genetic therapy is currently costly and might not be accessible to all patients, especially the poor ones who are afflicted with Hb disorders, especially red cell disorders like sickle cell or thalassemia.
Conclusion
Gene therapy presents an unprecedented strategy for managing hemoglobinopathies that focuses on curative approaches as one reduces the problem from the genetic aspect. Although some challenges still exist, such as technical, ethical, and safety-related barriers, the strides made in recent years have been successful. More work is needed on the basic science and clinical testing of these therapeutics so that their therapies can significantly improve safety and be more readily available to the patient population globally.
